Skip to content
Home
Team
Therapies
Overview/Pipeline
IC/BPS
Alenura™
Investor
News
Contact Us
Investor Login
  • November 25, 2020

Closing of shareholder offering

Home
/
Investor News
/
Closing of shareholder offering
Share Post:

Vaneltix announces the results of the 2020 Stockholder Offering and Bridge Loan Conversion: The company raised additional proceeds of $900,000 and all the Bridge Loans were converted into Common Stock at their respective conversion prices. All the conversions and purchases were eligible to apply for the Angel Investor NJ Tax Credit, and as a result of the 2020 Securities Modification and the Stockholder Offering, the Company is for the first time mainly debt free and the Company has no liens nor encumbrances on its assets.

NextNext

Stay Connected

More Updates

Vaneltix planning to enroll subjects in new round of clinical trials

On Tuesday, February 21st 2023, Bound Brook, NJ – Vaneltix Pharma, Inc. (Formerly Urigen Pharmaceuticals, Inc.; “Vaneltix” or “the Company”), a specialty pharmaceutical company focused

February 21, 2023

Vaneltix enters joint development agreement with Hyloris Pharmaceuticals

On Thursday, December 16, Vaneltix entered into a Joint Development Agreement with Hyloris Pharmaceuticals NV, a Belgian pharmaceuticals company (“Hyloris”) with respect to Vaneltix’s Alenura™

December 21, 2021
Vaneltix Pharma, Inc.
305 E High Street, Ste. 7,
Bound Brook, NJ 08805
United States
  • Tel:

    (732) 369-5911
  • Fax:

    (732) 356-1125
  • Email:

    Info@vaneltix.com
Team
Therapies
Investor
News
Contact Us
2021 © Vaneltix. All rights reserved.
Privacy Policy
Privacy Policy
This website is created by Blink.